|
®: CRE Regulatory Action of the Week
FDA Sees EU Dioxin Limits as Source of Trade Dispute
The threatened trade war looms as EPA wrestles with the bottom line of its long awaited dioxin risk assessment, and litigation over the reassessment continues. In 2000, EPA released a draft version of the report stating that dioxin posed cancer risks as high as 1 in 100 for some individuals. Last year EPA's Science Advisory Board cast doubt on the agency's draft report, however, with a majority of the SAB members voting against classifying dioxin as carcinogenic to humans. CRE Board Member Jim Tozzi and other plaintiffs have sued EPA over the dioxin report, and the new trade dispute will raise the stakes in that suit for both the FDA and industry. A final EPA dioxin reassessment classifying the chemical as "carcinogenic to humans" would significantly undermine arguments of the FDA and others challenging the severity of the EU's new regulations.
Tozzi has written to CVM Director Sundlof to alert him to the potential negative effects of the EPA dioxin reassessment on U.S. feed exports. Tozzi's letter urges Sundlof and CVM to participate actively in the upcoming interagency review of the EPA dioxin reassessment and to oppose issuance of the alarming "carcinogenic to humans" hazard classification.
|